Premium
Purified roswell park cultured antilymphocytie globulin RPMI‐CALG: Preparation and clinical trial
Author(s) -
Moore G. E.,
Murphy G. P.,
Papermaster B. W.,
Amiraian K.,
Kenny G. M.,
Moore R. H.
Publication year - 1969
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930010208
Subject(s) - medicine , globulin , prednisone , azathioprine , in vitro , immunology , clinical trial , platelet , eosinophilia , pharmacology , gastroenterology , biochemistry , biology , disease
Purified human antilymphocytic globulin (RPMI‐CALG) has been prepared in bulk quantities by immunization of horses with purified normal lymphocytes maintained in continuous cell culture at the Roswell Park Cell Plant. The characterization studies herein described reveal RPMI‐CALG to be purified, nontoxic, and nonpyrogenic with specific in vitro immunosuppressive activity. Contamination with hemolysins and hemagglutinins is minimal and in marked contrast to other available preparations. Initial clinical trials with a lyophilized preparation reveal that it can be safely administered intravenously to humans without untoward effects. Comparison of hematological data was made on patients receiving RPMI‐CALG pretransplant without other immunosuppressive agents to the same patients post‐transplant receiving RPMI‐CALG plus azathioprine and prednisone. No significant depressive hematological effect was apparent. Platelets were not depressed. Eosinophilia was not seen acutely or on follow‐up examination. Urticaria was not evident. Follow‐up studies up to 6 months after allografting failed to reveal any specific toxicity in the measured hematological parameters. This purified preparation merits further clinical trial.